A phase i study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 313-320

  Kowalski, Mark ^a   Entwistle, Joycelyn ^b   Cizeau, Jeannick ^b   Niforos, Demi ^a   Loewen, Shauna ^b   Chapman, Wendy ^a   Macdonald, Glen C ^b  

^a Viventia Biotech Inc   (Canada)

^b Viventia Biotech Inc   (Canada)

Author keywords

Anti EpCAM; Fusion protein; Pseudomonas exotoxin A; Targeted therapy

Indexed keywords

BCG VACCINE; EPITHELIAL CELL ADHESION MOLECULE; EXOTOXIN; EXOTOXIN A; OPORTUZUMAB MONATOX; UNCLASSIFIED DRUG; VB 4 845; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; HYBRID PROTEIN; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; ALOPECIA; ANOREXIA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLADDER BLEEDING; BLADDER CANCER; BLADDER SPASM; CANCER GRADING; CHILL; CONTROLLED STUDY; COUGHING; CYSTITIS; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSURIA; ENURESIS; ERYTHEMA; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATURIA; HUMAN; HYPOTENSION; IMMUNOGENICITY; INCONTINENCE; INJECTION SITE DISCOMFORT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; NECK PAIN; NOCTURIA; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRURITUS; RASH; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SORE THROAT; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; XEROSTOMIA; AGED; BLADDER TUMOR; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; FOLLOW UP; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79952483522     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S14071     Document Type: Article

References (20)

1. Bladder Cancer Version 1. Jenkintown (PA): National Comprehensive Cancer Network (NCCN); 2005. Clinical Practice Guidelines in Oncology, Version 1. 2008. Available from: http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Accessed 2009 Nov 4.
2. Shah SC, Kusiak A, O'Donnell MA. Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment. Comput Biol Med. 2006;36(6):634-655.
3. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials. J Urol. 2002;168(5):1964-1970.
4. Sylvester RJ, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005; 66(6 Suppl 1):90-107.
5. Boyd LA. Intravesical Bacillus Calmette-Guerin for treating bladder cancer. Urol Nurs. 2003;23(3):189-191, 199.
6. Witjes JA, Moonen PM, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology. 2006;67(4):751-755.
7. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol. 1997;139(5):1337-1348.
8. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77(10):699-712
9. Zorzos J, ZiZi A, Bakiras A, et al. Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Eur Urol. 1995;28(3):251-254.
10. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol. 2008;61(3):307-310.
11. Anagnostaki E, Skarlos D, Tamvakis N, et al. Immunohistochemical and immunocytochemical study of bladder carcinomas using the epitheliumspecific tumour-associated monoclonal antibodies HMFG1 and AUA1. Br J Cancer Suppl. 1990;10:52-56.
12. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9(7):2837-2848.
13. Keppler-Hafkemeyer A, Brinkmann U, Pastan I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry. 1998;37(48):16934-16942.
14. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559-565.
15. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res. 2000;6(2):326-334
16. Azemar M, Djahansouzi S, Jager E, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat. 2003;82(3):155-164.
17. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25(7):837-844.
18. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A Phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2008;2:105-114.
19. Brown J, Rasamoelisolo M, Spearman M, et al. Preclinical assessment of an anti-EpCAM Immunotoxin: locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm. 2009;24(4):477-487.
20. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18(8):1622-1636.